Destiny Pharma PLC unveils further positive results for c-difficile treatment as market research points to its commercial potential
NTCD-M3, which researchers are readying to phase III scientific trials, was the subject matter to
Destiny
Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021
Future Pharma PLC (Goal:DEST) (Future Pharma PLC (Goal:DEST)) is a clinical phase, innovative biotechnology organization
Destiny Pharma PLC looks to build on the progress made with its two key assets
The enterprise is blazing a trail in the infection arena and reckons it has two
Destiny Pharma PLC teams up with US Department of Veterans Affairs to find ‘new attributes’ for its next-generation antibiotic
NTCD-M3 is staying developed to beat Clostridioides difficile bacterial infections (CDI) in the gut ()
Destiny Pharma PLC making significant strides towards phase III evaluation of potential breakthrough C.diff treatment
CEO Neil Clark reported: “We have created important progress due to the fact closing the